(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number
WO 03/106708 A1

(51) International Patent Classification: C12Q 1/68, A61K 38/00, C07K 16/18

(21) International Application Number: PCT/GB03/02487

(22) International Filing Date: 10 June 2003 (10.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0213580.4 13 June 2002 (13.06.2002) GB
60/388,692 14 June 2002 (14.06.2002) US

(71) Applicant *(for all designated States except US)*: **ASTRAZENECA AB** [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant *(for MG only)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **MOORE, Rachael** [GB/GB]; AstraZeneca R & D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR THE DETECTION OF POLYMORPHISMS IN THE HUMAN OATPF GENE



(57) Abstract: The invention provides a method for the detection of a polymorphism in OATPF in a human. The method for detection of a nucleic acid polymorphism is selected from amplification refractory mutation system and restriction fragment length polymorphism. The invention also provides use of the method to assess the pharmacogenetics of a drug transportable by OATF.

WO 03/106708 A1

METHODS FOR THE DETECTION OF POLYMORPHISMS IN THE HUMAN OATPF GENE

This invention relates to polymorphisms in the human OATPF gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and materials for analysing allelic variation in the OATPF gene, and to the use of OATPF polymorphism in treatment of diseases with OATPF transportable drugs.

Membrane transporters are important for the absorption of oral medications across the gastrointestinal tract, uptake in to target tissues such as the liver or brain, and excretion into the bile and urine. Changes in the activities of transporters may therefore have a significant effect on the bioavailability of clinically important drugs.

It has been reported in the literature that polymorphisms in proteins involved in drug transport can alter the function of the protein. For example, the multidrug-resistance (MDR-1) gene contains a polymorphism in exon 26 (C3435T) which has been correlated with expression levels and function of MDR-1. Individuals homozygous for this polymorphisms have significantly lower duodenal MDR-1 expression and high digoxin plasma levels, suggesting this polymorphism affects the absorption and tissue concentrations of substrates of MDR-1 (S Hoffmeyer *et al.* Proceedings National Academy Science (2000) 97, 3473-3478).

The human sodium independent organic anion transporting polypeptide (OATP) F gene is a member of the OATP supergene family involved in multifunctional transport of organic anions (I. Tamai *et al.* Biochemical and Biophysical Research Communications 273, 251-260 (2000); M. Kusuhara &Y. Sugiyama Journal of Controlled Release 78 (2002) 43-54). There is an alternative nomenclature for this family as SLC21A (solute carriers) and OATPF relates to SLC21A14. A cDNA sequence encoding OATPF has been submitted to the EMBL database under accession number AF260704. A cDNA sequence encoding for OATPF has also been submitted to the EMBL database under accession number AF205076, and has been accorded the alternative name for OATPF of OATPRP5.

OATPF has a 43% identity at the amino acid level with its gene family member human OATPC (SLC21A6). OATPC has been shown to be involved in the transport of drugs involved in lipid lowering e.g. statins (D. Nakai *et al.* J Pharmacol Exp Ther 2001 297: 861-867). Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases (B. Hsiang *et al.* J. Biol Chem 274, 37161-37168 (1999)). Due to its sequence homology, it is likely that OATPF may transport similar substrates as OATPC. OATPF is also

homologous to a rat gene named BSAT1. BSAT1 is expressed at the blood-brain barrier in rats and human homologues of this gene may be important in transport of pharmaceutical agents into the brain.

DNA polymorphisms are variations in DNA sequence between one individual and another. DNA polymorphisms may lead to variations in amino acid sequence and consequently to altered protein structure and functional activity. Polymorphisms may also affect mRNA synthesis, maturation, transportation and stability. Polymorphisms which do not result in amino acid changes (silent polymorphisms) or which do not alter any known consensus sequences may nevertheless have a biological effect, for example by altering mRNA folding or stability.

Knowledge of polymorphisms may be used to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

The first 54bp of genomic DNA sequence immediately upstream of the OATPF protein coding sequence is set out as SEQ ID NO: 15, with the first nucleotide of the genomic DNA sequence accorded position 1. The position of the polymorphism in the genomic DNA sequence is defined with reference to SEQ ID NO: 15 unless stated otherwise or apparent from the context.

A cDNA sequence encoding OATPF is set out as SEQ ID NO: 16, with the first nucleotide of the OATPF coding region accorded position 65. All positions of polymorphisms in the human OATPF gene transcribed into messenger RNA (and thence cDNA) herein refer to the positions in SEQ ID NO: 16 unless stated otherwise or apparent from the context.

All positions herein of polymorphisms in the OATPF polypeptide are defined with reference to SEQ ID NO: 17 unless stated otherwise or apparent from the context.

The present invention is based on the discovery of four polymorphisms in the human OATPF gene and one polymorphism in the genomic DNA sequence immediately upstream of the human OATPF gene. The polymorphisms of the present invention may have a functional effect on the protein and hence alter the transport of pharmaceutical agents.

According to one aspect of the present invention there is provided a method for the detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at any one of the following positions: position 11-16 of SEQ ID NO: 15; positions 86, 505, 1339, 1991 of SEQ ID NO: 16; position 8 of SEQ ID NO: 17.

The term "human" includes both a human having or suspected of having an OATPF mediated response to a drug and an asymptomatic human who may be tested for predisposition or susceptibility to such a response. At each position the human may be homozygous for an allele or the human may be a heterozygote.

The term "detection of a polymorphism" refers to determination of the genetic status of an individual at a polymorphic position (in which the individual may be homozygous or heterozygous at each position).

The term "OATPF mediated response" means any disease in which changing the level of an OATPF mediated response or changing the biological activity of OATPF would be of therapeutic benefit.

The term "polymorphism" includes nucleotide substitution, nucleotide insertion and nucleotide deletion, which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene and variable numbers of a repeated DNA sequence.

In one embodiment of the invention preferably the polymorphism is further defined as: polymorphism at position 11-16 is presence of TAAAAA and/or insertion of ACTTTGAAAG in lieu thereof;

polymorphism at position 86 is presence of A and/or G;
polymorphism at position 505 is presence of C and/or T;
polymorphism at position 1339 is presence of A and/or G;
polymorphism at position 1991 is presence of A and/or T; and
polymorphism at position 8 is presence of Asn and/or Asp.

The polymorphism at position 11-16 of SEQ ID NO: 15 is the result of a deletion-insertion event defined as deletion of bases 11-16 of SEQ ID NO: 15 and insertion of ACTTTGAAAG in lieu thereof. This results in an overall extra four bases and it will be appreciated by the skilled person that this will have an effect on the numbering of positions downstream of this. For example, position 17 of SEQ ID NO: 15 becomes position 21 after the deletion-insertion event. It will also be appreciated by the skilled person that it may not be necessary to sequence the entire 11-16 bases or the insertion at this position to distinguish between the two alleles. For example, position 11 is either a T or an A when comparing the sequence of the two alleles.

In Figure 1, the polymorphism at position 11-16 is shown relative to the +1 ATG start site of the OATPF gene (position 65 as defined in SEQ ID NO: 16). Splicing of the genomic DNA sequence of Fig. 1 results in excision of the intronic region to produce a spliced 5' UTR (position 1-64 as defined in SEQ ID NO: 16) immediately upstream of the OATPF gene.

Preferred methods for detection of nucleic acid polymorphism are amplification refractory mutation system and restriction fragment length polymorphism.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a

number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
DHPLC	Denaturing high performance liquid chromotography
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OATP	Na+-independent organic anion transporting polypeptide
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis
UTR	Untranslated region

Table 1 - Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

* Note: not useful for detection of promoter polymorphisms.

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 95/13399 (Public Health Inst., New York)

Extension Based: ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

Restriction Enzyme Based: RFLP, Restriction site generating PCR

Ligation Based: OLA

Other: Invader assay

Table 2 - Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 - Further Amplification Methods

SSR, NASBA, LCR, SDA, b-DNA

Table 4- Protein variation detection methods

Immunoassay

Immunohistology

Peptide sequencing

Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2nd edition, C P Price & D J Newman, 1997, published by Stockton Press in USA & Canada and by Macmillan Reference in the United Kingdom. Histological techniques are known in the art e.g. Theory and Practice of Histological Techniques, 4th Edition, edited by JD Bancroft and A Stevens, Churchill Livingstone, 1996. Protein sequencing is described in Laboratory techniques Biochemistry and Molecular Biology, Volume 9, Sequencing of Proteins and Polypeptides, G Allen, 2nd revised edition, Elsevier, 1989.

Preferred mutation detection techniques include ARMS™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, restriction site based PCR and FRET techniques, polyacrylamide gel electrophoresis and capillary electrophoresis.

Particularly preferred methods include ARMS™ and RFLP based methods. ARMS™ is an especially preferred method.

In a further aspect, the methods of the invention are used to assess the pharmacogenetics of a drug transportable by OATPF.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

Individuals who carry particular allelic variants of the OATPF gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The methods of the invention may be useful both to predict the clinical response to such agents and to determine therapeutic dose.

In a further aspect, the methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by OATPF. The present invention may be used to recognise individuals who are particularly at risk from developing such diseases.

In a further aspect, the methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the OATPF gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the disease process whilst minimising effects on other variants.

In a further aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

According to another aspect of the present invention there is provided a human OATPF gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic variant selected from any of the following:

Region	variant	Position
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-16 (SEQ ID NO: 15)

According to another aspect of the present invention there is provided a human OATPF gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 20 bases comprising at least one polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

According to another aspect of the present invention there is provided an allele specific primer capable of detecting an OATPF gene polymorphism, preferably at one or more of the positions as defined herein.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1993; 1st Edition. If required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting an OATPF gene polymorphism, preferably at one or more of the positions defined herein.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

According to another aspect of the present invention there is provided an allele specific primer or an allele specific oligonucleotide probe capable of detecting an OATPF gene polymorphism at one of the positions defined herein.

According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

In another aspect of the invention, the polymorphisms of this invention may be used as genetic markers in linkage studies. This particularly applies to the polymorphisms of relatively high frequency. The OATPF gene is on chromosome 12. Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal

or maternal) chromosome. If recombination within the gene is random, there may be as many as 2^n haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that polymorphisms with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency polymorphisms may be particularly useful in identifying these mutations (for examples see: De Stefano V *et al. Ann Hum Genet* (1998) 62:481-90; and Keightley AM *et al. Blood* (1999) 93:4277-83).

According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology searching, mapping, haplotyping, genotyping or pharmacogenetic analysis or any other bioinformatic analysis. The reader is referred to Bioinformatics, A practical guide to the analysis of genes and proteins, Edited by A D Baxevanis & B F F Ouellette, John Wiley & Sons, 1998. Any computer readable medium may be used, for example, compact disk, tape, floppy disk, hard drive or computer chips.

The polynucleotide sequences of the invention, or parts thereof, particularly those relating to and identifying the polymorphisms identified herein represent a valuable information source, for example, to characterise individuals in terms of haplotype and other sub-groupings, such as investigation of susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a computer readable medium and then using the information in standard bioinformatics programs or to search sequence databases using state of the art searching tools such as "GCC". Thus, the polynucleotide sequences of the invention are particularly useful as components in databases useful for sequence identity and other search analyses. As used herein, storage of the sequence information in a computer readable medium and use in sequence databases in relation to 'polynucleotide or polynucleotide sequence of the invention' covers any detectable chemical or physical characteristic of a polynucleotide of the invention that may be reduced to, converted into or stored in a tangible medium, such as a computer

disk, preferably in a computer readable form. For example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data.

The invention provides a computer readable medium having stored thereon one or more polynucleotide sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a polynucleotide comprising the sequence of a polynucleotide of the invention, a polynucleotide consisting of a polynucleotide of the invention, a polynucleotide which comprises part of a polynucleotide of the invention, which part includes at least one of the polymorphisms of the invention, a set of polynucleotide sequences wherein the set includes at least one polynucleotide sequence of the invention, a data set comprising or consisting of a polynucleotide sequence of the invention or a part thereof comprising at least one of the polymorphisms identified herein.

A computer based method is also provided for performing sequence identification, said method comprising the steps of providing a polynucleotide sequence comprising a polymorphism of the invention in a computer readable medium; and comparing said polymorphism containing polynucleotide sequence to at least one other polynucleotide or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymorphism.

According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:

i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of: position 15-24 of SEQ ID NO: 15; positions 86, 505, 1339 and 1991 of SEQ ID NO: 16; position 8 of SEQ ID NO: 17; and

ii) administering an effective amount of the drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which statin drug or drugs to administer and/or in deciding on the effective amount of the statin drug or drugs. Statins already approved for use in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. Statins under development include rosuvastatin. The reader is referred to the following references for further information: Drugs and Therapy Perspectives (12th May 1997), 9: 1-6; Chong (1997)

Pharmacotherapy 17: 1157-1177; Kellick (1997) Formulary 32: 352; Kathawala (1991) Medicinal Research Reviews, 11: 121-146; Jahng (1995) Drugs of the Future 20: 387-404, and Current Opinion in Lipidology, (1997), 8, 362 – 368; Olsson AG, Pears J, McKellar J, Mizan J & Raza A (2001) American Journal of Cardiology 88(5): 504-508. The term "drug transportable by OATPF" means that transport by OATPF in humans is an important part of a drug exerting its pharmceutical effect in man. For example, some statins have to be transported to the liver by OATPC, which is highly homologous to OATPF, to exert their lipid lowering effects. Accordingly, OATPF is expected to be involved in statin transport.

According to another aspect of the present invention there is provided use of a drug transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism defined herein.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising OATPF transportable drug and instructions for administration of the drug to humans tested for a polymorphism described therein, preferably at one or more of the positions defined herein.

One of the polymorphisms of the present invention result in variation in the amino acid sequence of the translated protein. Polymorphism at position 86 as defined in SEQ ID NO: 16 results in an amino acid change from asparagine to aspartic acid at corresponding position 8 of the translated protein (Asn8Asp) as defined in SEQ ID NO: 17.

Thus according to another aspect of the present invention there is provided an allelic variant of human OATPF polypeptide having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

Fragments of OATPF polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids. The polypeptides of the invention do not encompass naturally occurring polypeptides as they occur in nature, for example, the polypeptide is at least partially purified from at least one component with which it occurs naturally. Preferably the polypeptide is at least 30% pure, more preferably at least 60% pure, more preferably at least 90% pure, more preferably at least 95% pure, and more preferably at least 99% pure.

According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human OATPF polypeptide having an aspartic acid at position

8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to include polycional antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example $F(ab')_2$, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of OATPF with a K_a of greater than or equal to about 10^7 M^{-1}. Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660 (1949).

Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster immunizations, small samples of serum are collected and tested for reactivity to antigen. Examples of various assays useful for such determination include those described in: *Antibodies: A Laboratory Manual*, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; Monoclonal Antibodies, Hybridomas: *A New Dimension in Biological Analyses,* Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

According to another aspect of the invention there is provided a diagnostic kit comprising an antibody of the invention.

The invention will now be illustrated but not limited by reference to the following Examples and Figure 1 is a schematic representation of the genomic DNA sequence upstream of Exon 1 of the OATPF gene, and shown relative to the corresponding nucleotide positions of SEQ ID NO: 15 and SEQ ID NO: 16. All temperatures are in degrees Celsius.

In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

AMPLITAQ™ ,available from Perkin-Elmer Cetus, may be used as the source of thermostable DNA polymerase.

General molecular biology procedures can be followed from any of the methods described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) or in "Current Protocols in Molecular Biology Volumes1-3 , edited by F M Asubel, R Brent and R E Kingston; published by John Wiley, 1998.

EXAMPLES

Example 1

Identification of Polymorphisms

1. Methods

The cDNA sequence of OATPF (AF260704) was used to identify the genomic position of the gene and obtain genomic DNA sequence. The genomic DNA sequence was used to design PCR primers to amplify over the exons and intron/exon boundaries of the full length of the OATP gene. Twenty-nine individual Caucasian genomic DNA samples were used as templates for PCR amplification. The products were then sequenced by dye-primer sequencing using Amersham's MegaBACE™ technology. The alignment of sequence traces enabled the identification of polymorphisms. The frequency of the polymorphisms was confirmed using genomic DNA from 20 individuals by primer extension analysis by DHPLC using the WAVE® system by Transgenomics and also by sequencing as described above. The deletion-insertion event was confirmed by sequencing in the forward and reverse direction.

PCR products

Polymorphism	PCR forward oligo	PCR reverse oligo	Primer used for confirmation of polymorphism
Exon 1	(SEQ ID NO: 1)	(SEQ ID NO: 2)	(SEQ ID NO: 3)
Exon 4	(SEQ ID NO: 4)	(SEQ ID NO: 5)	(SEQ ID NO: 6)
Exon 9	(SEQ ID NO: 7)	(SEQ ID NO: 8)	(SEQ ID NO: 9)
Exon 14	(SEQ ID NO: 10)	(SEQ ID NO: 11)	(SEQ ID NO: 12)
Intronic	(SEQ ID NO: 13)	(SEQ ID NO: 14)	N/a

PCR conditions:

18µl ABgene 2mM Reddy load including Taq polymerase

1µl 5µM primer pair mix

1µl genomic DNA (various individuals)

PCR programme:

94°C 1min; (94°C 30sec, 58°C 30sec, 72°C 2 min) for 34 cycles; 72°C 10 min.

2. OATPF Polymorphisms

Sequencing of DNA from 20 individuals identified the following 5 polymorphisms in the OATPF DNA sequence:

Position of SEQ ID NO 16	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
86	Exon 1	A/G	aat-gat	Asn8Asp	0.03G
505	Exon 4	C/T	N/a	Ser147Ser	0.46T
1339	Exon 9	A/G	N/a	Ala425Ala	0.05G
1991	Exon 14	C/T	N/a	Leu643Leu	0.25T

Position of SEQ ID NO: 15	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
11-16	Intronic	TAAAAA/ ACTTTGA AAG	N/a	N/a	0.06ACTTTGAAAG

Claims

1. A method for the detection of a polymorphism in OATPF in a human which method comprises determining the sequence of the human at any one of the following positions:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
position 8 of SEQ ID NO: 17.

2. A method according to claim 1 wherein the polymorphism is further defined as:
polymorphism at position 11-16 is presence of TAAAAA and/or insertion of ACTTTGAAAG in lieu thereof;
polymorphism at position 86 is presence of A and/or G;
polymorphism at position 505 is presence of C and/or T;
polymorphism at position 1339 is presence of A and/or G;
polymorphism at position 1991 is presence of A and/or T; and
polymorphism at position 8 is presence of Asn and/or Asp.

3. A method according to claim 1 or 2 wherein the method for detection of a nucleic acid polymorphism is selected from amplification refractory mutation system and restriction fragment length polymorphism.

4. Use of a method defined in any of claims 1-3 to assess the pharmacogenetics of a drug transportable by OATPF.

5. A polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic variant selected from any of the following:

Region	variant	Position
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-20 (SEQ ID NO: 15)

6. An allele specific primer capable of detecting an OATPF gene polymorphism at position 11-16 of SEQ ID NO: 15, and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.

7. An allele specific oligonucleotide probe capable of detecting a OATPF gene polymorphism at position 11-16 of SEQ ID NO: 15 and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.

8. A diagnostic kit comprising an allele specific oligonucleotide probe of claim 7 and/or an allele-specific primer of claim 6.

9. A method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:

i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of:

position 11-16 of SEQ ID NO: 15;

positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;

position 8 of SEQ ID NO: 17; and

ii) administering an effective amount of the drug.

10. Use of a drug transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism at one of the following positions:

position 11-16 of SEQ ID NO: 15;

positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;

position 8 of SEQ ID NO: 17.

11. An allelic variant of human OATPF polypeptide comprising an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

12. An antibody specific for an allelic variant of human OATPF polypeptide as described herein having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

13. A diagnostic kit comprising an antibody of claim 12.

Figure 1


-3809
-3769
-38
-25
1
129
5'UTR
Intronic
5'UTR
Exon 1 of OATPF
10bp
substitution
SEQ ID NO: 16
1
39
40
65
SEQ ID NO: 15
1
11
16
29
54

SEQUENCE LISTING

<110> ASTRAZENECA AB

<120> METHODS

<130> JHU/100692-1 GB 09APR02

<140>

<141>

<160> 17

<170> PatentIn Ver. 2.1

<210> 1
<211> 40
<212> DNA
<213> Artificial Sequence

<400> 1
actgtaaaac gacggccagt aatgaggctt aaactgggca 40

<210> 2
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR reverse primer OATPF-1R

<400> 2
accaggaaac agctatgacc ggtagagatt gcttgcaccg 40

<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Validation primer

<400> 3
tggacacttc atccaaagaa 20

<210> 4
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR forward primer OATPF-2P

<400> 4
actgtaaaac gacggccagt ctatgagcca gatcttctgg c 41

<210> 5
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR reverse primer OATPF-2R

<400> 5
accaggaaac agctatgacc cagaagcttt gaaagatttt ccc 43

<210> 6
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Validation primer

<400> 6
tattctcctt cctccaattc 20

<210> 7

<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR forward primer OATPF-3F

<400> 7
actgtaaaac gacggccagt tgggcaccta attgctacct 40

<210> 8
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR reverse primer OATPF-3R

<400> 8
accaggaaac agctatgacc tgagggaaca taccttggt 40

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Validation primer

<400> 9
atcagtgtgt gtggagctgc 20

<210> 10
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR forward

primer OATPF-4F

<400> 10
actgtaaaac gacggccagt gctgttctag gcaaacaggg 40

<210> 11
<211> 16
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR reverse primer OATPF-4R

<400> 11
ccagtagttg ggttgt 16

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Validation primer

<400> 12
cttcttctag acatatatat 20

<210> 13
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR forward primer OATPF-5F

<400> 13
actgtaaaac gacggccagt cttcagctct ttctgtgccc 40

<210> 14
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR reverse primer OATPF-5R

<400> 14
accaggaaac agctatgacc ttccatcaaa ctaatgaggg g 41

<210> 15
<211> 54
<212> DNA
<213> Homo sapiens

<400> 15
atttttactt taaaaactaa ctttgacaga tcagagtcaa ggaatgtgtt tata 54

<210> 16
<211> 3077
<212> DNA
<213> Homo sapiens

<400> 16
cattgaaagg aaatggctat ctttgatctc ttcctccaga tcagagtcaa ggaatgtgtt 60
tataatggac acttcatcca aagaaaatat ccagttgttc tgcaaaactt cagtgcaacc 120
tgttggaagg ccttctttta aaacagaata tccctcctca gaagaaaagc aaccatgctg 180
tggtgaacta aaggtgttct tgtgtgcctt gtcttttgtt tactttgcca aagcattggc 240
agaaggctat ctgaagagca ccatcactca gatagagaga aggtttgata tcccttcttc 300
actggtggga gttattgatg gtagttttga aattgggaat ctcttagtta taacatttgt 360
tagctacttt ggagccaaac ttcacaggcc aaaaataatt ggagcagggt gtgtaatcat 420
gggagttgga acactgctca ttgcaatgcc tcagttcttc atggagcagt acaaatatga 480
gagatattct ccttcctcca attccactct cagcatctct ccgtgtctcc tagagtcaag 540
cagtcaatta ccagtttcag ttatggaaaa atcaaaatcc aaaataagta acgaatgtga 600
agtggacact agctcttcca tgtggattta tgttttcctg ggcaatcttc ttcgtggaat 660
aggagaaact cccattcagc ctttgggcat tgcctacctg gatgattttg ccagtgaaga 720
caatgcagct ttctatattg ggtgtgtgca gacggttgca attataggac caatctttgg 780
tttcctgtta ggctcattat gtgccaaact atatgttgac attggctttg taaacctaga 840
tcacataacc attaccccaa aagatcccca gtgggtagga gcctggtggc ttggctatct 900
aatagcagga atcataagtc ttcttgcagc tgtgcctttc tggtatttac caaagagttt 960
accaagatcc caaagtagag aggattctaa ttcttcctct gagaaatcca agtttattat 1020

agatgatcac acagactacc aaacacccca gggagaaaat gcaaaaataa tggaaatggc 1080
aagagatttt cttccatcac tgaagaatct ttttggaaac ccagtatact tcctatattt 1140
atgtacaagc actgttcagt tcaattctct gttcggcatg gtgacgtaca aaccaaagta 1200
cattgagcag cagtatggac agtcatcctc cagggccaac tttgtgatcg ggctcatcaa 1260
cattccagca gtggcccttg gaatattctc tgggggata gttatgaaaa aattcagaat 1320
cagtgtgtgt ggagctgcaa aactctactt gggatcatct gtctttggtt acctcctatt 1380
tctttccctg tttgcactgg gctgtgaaaa ttctgatgtg gcaggactaa ctgtctccta 1440
ccaaggaacc aaacctgtct cttatcatga acgagctctc ttttcagatt gcaactcaag 1500
atgcaaatgt tcagagacaa aatgggaacc catgtgcggt gaaaatggaa tcacatatgt 1560
atcagcttgt cttgctggtt gtcaaacctc caacaggagt ggaaaaaata ttatatttta 1620
caactgcact tgtgtgggaa ttgcagcttc taaatccgga aattcctcag gcatagtggg 1680
aagatgtcag aaagacaatg gatgtcccca aatgtttctg tatttccttg taatttcagt 1740
catcacatcc tatactttat ccctaggtgg catacctgga tacatattac ttctgaggtg 1800
cattaagcca cagcttaagt cttttgcctt gggtatctac acattagcaa taagagttct 1860
tgcaggaatc ccagctccag tgtattttgg agttttgatt gatacttcat gcctcaaatg 1920
gggatttaaa agatgtggaa gtagaggatc atgcagatta tatgattcaa atgtcttcag 1980
acatatatat ctgggactaa ctgtgatact gggcacagtg tcaattctcc taagcattgc 2040
agtacttttc attttaaaga aaaattatgt ttcaaaacac agaagtttta taaccaagag 2100
agaaagaaca atggtgtcta caagattcca aaaggaaaat tacactacaa gtgatcatct 2160
gctacaaccc aactactggc caggcaagga aactcaactt tagaaacatg atgactggaa 2220
gtcatgtctt ctaattggtt gacattttgc aaacaaataa attgtaatca aaagagctct 2280
aaatttgtaa tttctttctc ctttcaaaaa atgtctactt tgttttggtc ctaggcatta 2340
ggtaatataa ctgataatat actgaaacat ataatggaag atgcagatga taaaactaat 2400
tttgaacttt ttaatttata taaattattt tatatcactt acttatttca ctttattttg 2460
ctttgtgctc attgatatat attagctgta ctcctagaag aacaattgtc tctattgtca 2520
cacatggtta tatttaaagt aatttctgaa ctgtgtaatg tgtctagagt aagcaaatac 2580
tgctaacaat taactcatac cttgggttcc ttcaagtatt actcctatag tattttctcc 2640
catagctgtc ttcatctgtg tattttaata atgatcttag gatggagcag aacatggaga 2700
ggaagatttc attttaagct cctccttttc tttgaaatac aataatttat atagaaatgt 2760
gtagcagcaa attatattgg ggattagaat tttgaattaa tagctctcct actattaatt 2820
tacatgtgct ttttgtgtgg cgctataagt gactatggtt gtaaagtaat aaaattgatg 2880
ttaacatgcc caattattgt tcttttatga attcaatgaa tttaaaacta ttgttaaata 2940
taatactgcc ccactttaat atatgtaagc aacttcctac ttatacacga cgtgttccta 3000
aaacatgttt gaaaggtgaa tttctgaaag tctacaataa atgtaggtgt tacaacagga 3060
aaaaaaaaaa aaaaaaa 3077

<210> 17
<211> 712
<212> PRT
<213> Homo sapiens

<400> 17
Met Asp Thr Ser Ser Lys Glu Asn Ile Gln Leu Phe Cys Lys Thr Ser
1 5 10 15

Val Gln Pro Val Gly Arg Pro Ser Phe Lys Thr Glu Tyr Pro Ser Ser
20 25 30

Glu Glu Lys Gln Pro Cys Cys Gly Glu Leu Lys Val Phe Leu Cys Ala
35 40 45

Leu Ser Phe Val Tyr Phe Ala Lys Ala Leu Ala Glu Gly Tyr Leu Lys
50 55 60

Ser Thr Ile Thr Gln Ile Glu Arg Arg Phe Asp Ile Pro Ser Ser Leu
65 70 75 80

Val Gly Val Ile Asp Gly Ser Phe Glu Ile Gly Asn Leu Leu Val Ile
85 90 95

Thr Phe Val Ser Tyr Phe Gly Ala Lys Leu His Arg Pro Lys Ile Ile
100 105 110

Gly Ala Gly Cys Val Ile Met Gly Val Gly Thr Leu Leu Ile Ala Met
115 120 125

Pro Gln Phe Phe Met Glu Gln Tyr Lys Tyr Glu Arg Tyr Ser Pro Ser
130 135 140

Ser Asn Ser Thr Leu Ser Ile Ser Pro Cys Leu Leu Glu Ser Ser Ser
145 150 155 160

Gln Leu Pro Val Ser Val Met Glu Lys Ser Lys Ser Lys Ile Ser Asn
165 170 175

Glu Cys Glu Val Asp Thr Ser Ser Ser Met Trp Ile Tyr Val Phe Leu
180 185 190

Gly Asn Leu Leu Arg Gly Ile Gly Glu Thr Pro Ile Gln Pro Leu Gly
195 200 205

Ile Ala Tyr Leu Asp Asp Phe Ala Ser Glu Asp Asn Ala Ala Phe Tyr
210 215 220

Ile Gly Cys Val Gln Thr Val Ala Ile Ile Gly Pro Ile Phe Gly Phe
225 230 235 240

Leu Leu Gly Ser Leu Cys Ala Lys Leu Tyr Val Asp Ile Gly Phe Val
245 250 255

```
Asn Leu Asp His Ile Thr Ile Thr Pro Lys Asp Pro Gln Trp Val Gly
            260                 265                 270

Ala Trp Trp Leu Gly Tyr Leu Ile Ala Gly Ile Ile Ser Leu Leu Ala
        275                 280                 285

Ala Val Pro Phe Trp Tyr Leu Pro Lys Ser Leu Pro Arg Ser Gln Ser
    290                 295                 300

Arg Glu Asp Ser Asn Ser Ser Ser Glu Lys Ser Lys Phe Ile Ile Asp
305                 310                 315                 320

Asp His Thr Asp Tyr Gln Thr Pro Gln Gly Glu Asn Ala Lys Ile Met
                325                 330                 335

Glu Met Ala Arg Asp Phe Leu Pro Ser Leu Lys Asn Leu Phe Gly Asn
            340                 345                 350

Pro Val Tyr Phe Leu Tyr Leu Cys Thr Ser Thr Val Gln Phe Asn Ser
        355                 360                 365

Leu Phe Gly Met Val Thr Tyr Lys Pro Lys Tyr Ile Glu Gln Gln Tyr
    370                 375                 380

Gly Gln Ser Ser Ser Arg Ala Asn Phe Val Ile Gly Leu Ile Asn Ile
385                 390                 395                 400

Pro Ala Val Ala Leu Gly Ile Phe Ser Gly Gly Ile Val Met Lys Lys
                405                 410                 415

Phe Arg Ile Ser Val Cys Gly Ala Ala Lys Leu Tyr Leu Gly Ser Ser
            420                 425                 430

Val Phe Gly Tyr Leu Leu Phe Leu Ser Leu Phe Ala Leu Gly Cys Glu
        435                 440                 445

Asn Ser Asp Val Ala Gly Leu Thr Val Ser Tyr Gln Gly Thr Lys Pro
    450                 455                 460

Val Ser Tyr His Glu Arg Ala Leu Phe Ser Asp Cys Asn Ser Arg Cys
465                 470                 475                 480

Lys Cys Ser Glu Thr Lys Trp Glu Pro Met Cys Gly Glu Asn Gly Ile
                485                 490                 495
```

```
Thr Tyr Val Ser Ala Cys Leu Ala Gly Cys Gln Thr Ser Asn Arg Ser
            500                 505                 510

Gly Lys Asn Ile Ile Phe Tyr Asn Cys Thr Cys Val Gly Ile Ala Ala
        515                 520                 525

Ser Lys Ser Gly Asn Ser Ser Gly Ile Val Gly Arg Cys Gln Lys Asp
    530                 535                 540

Asn Gly Cys Pro Gln Met Phe Leu Tyr Phe Leu Val Ile Ser Val Ile
545                 550                 555                 560

Thr Ser Tyr Thr Leu Ser Leu Gly Gly Ile Pro Gly Tyr Ile Leu Leu
                565                 570                 575

Leu Arg Cys Ile Lys Pro Gln Leu Lys Ser Phe Ala Leu Gly Ile Tyr
            580                 585                 590

Thr Leu Ala Ile Arg Val Leu Ala Gly Ile Pro Ala Pro Val Tyr Phe
        595                 600                 605

Gly Val Leu Ile Asp Thr Ser Cys Leu Lys Trp Gly Phe Lys Arg Cys
    610                 615                 620

Gly Ser Arg Gly Ser Cys Arg Leu Tyr Asp Ser Asn Val Phe Arg His
625                 630                 635                 640

Ile Tyr Leu Gly Leu Thr Val Ile Leu Gly Thr Val Ser Ile Leu Leu
                645                 650                 655

Ser Ile Ala Val Leu Phe Ile Leu Lys Lys Asn Tyr Val Ser Lys His
            660                 665                 670

Arg Ser Phe Ile Thr Lys Arg Glu Arg Thr Met Val Ser Thr Arg Phe
        675                 680                 685

Gln Lys Glu Asn Tyr Thr Thr Ser Asp His Leu Leu Gln Pro Asn Tyr
    690                 695                 700

Trp Pro Gly Lys Glu Thr Gln Leu
705                 710
```

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02487

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68 A61K38/00 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12Q A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, EMBL, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00 71566 A (BRISTOL MYERS SQUIBB CO) 30 November 2000 (2000-11-30)	1-10
A	page 32, nucleotide 296 is a "T", i.e. this corresponds to Exon 14 variant of the present application, represented in SEQ ID No 16 as nucleotide 1991. claims 2,9	11-13
	-/-	

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
29 September 2003	14/10/2003

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Osborne, H

Form PCT/ISA/210 (second sheet) (July 1992)

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL 'Online! 30 November 2001 (2001-11-30) MAO Y ET AL: "Human tissue anion rotation polypeptide 41 coding sequence" retrieved from EBI Database accession no. AAI65135 XP002254957 Nucleotides 334 ("G") and 996 ("T") correspond to the exon 9 and 14 variants of the present application, represented in SEQ ID No 16 as nucleotide 1339 and 1991 respectively.	1-10
X	& CN 1 303 937 A (SHANGHAI BORONG GENE DEV CO LTD) 10 July 2001 (2001-07-10) page 17 -page 18; claim 6	1-10
A	EP 1 186 672 A (ASTRAZENECA AB) 13 March 2002 (2002-03-13) the whole document	1-11
P,X	EP 1 264 843 A (MILLENIUM PHARMACEUTICALS INC) 11 December 2002 (2002-12-11) SEQ ID No 22 at position 785 is a "T." This corresponds to the Exon 4 variant of the present application, represented in SEQ ID No 16 as nucleotide 505.	1-10
A	ULBRECHT M ET AL: "Assoziation of beta 2-adrenoreceptor variants with bronchial hyperresponsiveness" AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, AMERICAN LUNG ASSOCIATION, NEW YORK, NY, US, vol. 161, no. 2, February 2000 (2000-02), pages 469-474, XP002188594 ISSN: 1073-449X the whole document	1-4
A	DATABASE EMBL 'Online! Homosapiens organic anion transporter polypeptid, 17 May 2000 (2000-05-17) PIZZAGALLI F ET AL: "Identification of a new human organic anion transporter polypeptide OATP-F 14" retrieved from EMBL Database accession no. af260704 XP002205066 abstract	

-/—

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
A	IIDA ARITOSHI ET AL: "Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins" JOURNAL OF HUMAN GENETICS, XX, XX, vol. 46, no. 11, 2001, pages 668–683, XP002245996	

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02487

Box I. Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 9 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. [X] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claim 10 relates to the use of a compound (drug) transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism defined in claim 10.

In this particular case, the functional features of the drug used in the medicament is defined by the results to be achieved, namely that the drug/medicament is useable for treating a disease in a human and wherein said disease is associated with one of the selection of polymorphisms detailed in claim 10. Further definition of such disease is neither detailed in the claim or in the body of the patent application.

The claim covers all compounds (drugs) having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds (drugs). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compound (drug) by reference to a result to be achieved, and for an undefined disease(s) . Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the compounds (drugs) mentioned on page 11, lines 27 - 31 of the description, without restriction to a specific disease.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

PCT/GB 03/02487

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0071566 A	30-11-2000	AU 5278000 A	12-12-2000
		BR 0010552 A	13-02-2002
		CA 2374729 A1	30-11-2000
		CN 1351612 T	29-05-2002
		EP 1183270 A2	06-03-2002
		HU 0201303 A2	28-08-2002
		JP 2003500039 T	07-01-2003
		PL 351652 A1	19-05-2003
		WO 0071566 A2	30-11-2000
CN 1303937 A	18-07-2001	NONE	
EP 1186672 A	13-03-2002	EP 1186672 A2	13-03-2002
		JP 2002330758 A	19-11-2002
		US 2002090622 A1	11-07-2002
EP 1264843 A	11-12-2002	EP 1264843 A2	11-12-2002
		US 2002165357 A1	07-11-2002